947400-61-5

Basic information

• Product Name: 5-(3-fluorophenyl)-1-[2-(4-fluorophenyl)ethyl]-2-methyl-1H-pyrrole-3-carboxylic acid
• Synonyms: 5-(3-fluorophenyl)-1-[2-(4-fluorophenyl)ethyl]-2-methyl-1H-pyrrole-3-carboxylic acid
• CAS NO: 947400-61-5
• Molecular Weight: 341.357
• Mol File: 947400-61-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-(3-fluorophenyl)-1-[2-(4-fluorophenyl)ethyl]-2-methyl-1H-pyrrole-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-fluorophenyl)-1-[2-(4-fluorophenyl)ethyl]-2-methyl-1H-pyrrole-3-carboxylic acid(947400-61-5)
• EPA Substance Registry System: 5-(3-fluorophenyl)-1-[2-(4-fluorophenyl)ethyl]-2-methyl-1H-pyrrole-3-carboxylic acid(947400-61-5)

Safety Data

• Hazardous Substances Data: 947400-61-5(Hazardous Substances Data)

Upstream product

• 947400-60-4 methyl 5-(3-fluorophenyl)-1-[2-(4-fluorophenyl)ethyl]-2-methyl-1H-pyrrole-3-carboxylate 
• 947400-59-1 methyl 2-acetyl-4-(3-fluorophenyl)-4-oxobutanoate 
• 53631-18-8 2-bromo-1-(3-fluorophenyl)ethanone 
• 459-19-8 2-(4-fluorophenyl)ethylamine hydrochloride 

Downstream Products

• 947397-77-5 N-(diaminomethylene)-5-(3-fluorophenyl)-1-[2-(4-fluorophenyl)ethyl]-2-methyl-1H-pyrrole-3-carboxamide 

Relevant articles and documents

PYRROLE DERIVATIVE OR SALT THEREOF

[Problem] To provide a compound which may be used for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that a pyrrole derivative characterized by the possession of a guanidinocarbonyl group or amido group as a substituent group at the 3-position, or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).